Wuxi Shuhui Pharmaceutical

Wuxi Shuhui Pharmaceutical Technology is a specialized research and development subsidiary of WuXi AppTec, a global leader in pharmaceutical and biotech services. Based in Wuxi, China, the company serves as an internal incubator for the discovery and early-stage development of novel small molecule therapeutics. Wuxi Shuhui focuses on advancing candidates through medicinal chemistry, lead optimization, and IND-enabling studies, primarily in the fields of metabolic diseases, oncology, and inflammatory disorders. Its pipeline is characterized by the "WXSH" designation, with notable programs including small molecule GLP-1 receptor agonists for diabetes and obesity. The company leverages the extensive integrated infrastructure of its parent organization to develop high-potential assets for potential out-licensing or collaborative development with global partners.